Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2010

View Archived Issues

TIGER-1 data detail potential of denufosol in cystic fibrosis

7TM Pharma reports encouraging phase I data on TM-38837

FSH receptor is a possible marker of several cancer types

Vertex Pharma enrolls additional cohort in phase II telaprevir/VX-222 trial

Furiex Pharma presents phase II data on JNJ-Q2

Trans-sodium crocetinate is beneficial in PAD-related intermittent claudication

Suven Life Sciences presents SUVN-F90101 and SUVN-F91201

AB Therapeutics reports data on two anticancer agents in model of NSCLC

MicroDose Therapeutx receives Therapeutic Discovery Project grants

ProtAffin receives funding from Austrian FFG to develop PA-401

Abbott describes analgesic effects of A-1048400

Nektar Therapeutics presents new tyrosine protein kinase inhibitor-oligomer conjugates

XenoPort discloses new GABA(B) receptor ligands

Karus Therapeutics claims new histone deacetylase inhibitors

Italian scientists discover new selective androgen receptor modulators

FDA approves Eisai's Halaven for late-stage breast cancer

Pozen achieves milestone under Vivomo partnership with AstraZeneca

BioWa licenses Potelligent technology to Agensys

StemCells files application in Switzerland for clinical trial of HuCNS-SC

FluCide Nanoviricides reduce viral load in model of lethal flu

Agios Pharma claims new activators of pyruvate kinase isozymes M1/M2

Health Canada approves Vitaros as first-line therapy for erectile dysfunction

Amakem receives Flemish IWT grant for ROCK inhibitor program in COPD

Merrion Pharma plans phase III study of Orazol in breast cancer

Horizon Pharma receives U.S. government grant for HZT-501

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.